Physician profile
Ramon Lee
NPI 1215496427
$5,104.94
in general payments reported to CMS, 2019-2025
22 companies · $1,799 in 2025
The $1,799 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $92.62 · 2023: $1,679 · 2024: $1,535 · 2025: $1,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,972 · Education: $39.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,972.33 |
| Education | $39.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $927.91 | 2023-2025 | Lifevest |
| Biotronik INC. | $822.50 | 2022-2025 | Acticor 7 Vr-T Dx, Amvia Edge, Edora 8 Dr-T |
| Boston Scientific Corporation | $763.53 | 2023-2025 | Watchman Flx, Opticross, Avvigo Guidance System |
| Shockwave Medical, INC | $719.73 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $422.94 | 2023-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $275.07 | 2024-2025 | |
| Kestra Medical Technology Services, INC. | $175.44 | 2024 | Assure Wcd |
| W. L. Gore & Associates, INC. | $162.96 | 2025 | Gore Cardioform Septal Occluder |
| Abiomed | $162.09 | 2023 | Impella |
| Merck Sharp & Dohme LLC | $124.46 | 2025 | Verquvo, Winrevair, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $108.32 | 2023-2025 | Camzyos |
| Pfizer INC. | $96.62 | 2023-2025 | |
| Procyrion, INC. | $66.21 | 2025 | Aortix System |
| Novo Nordisk INC | $59.99 | 2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $50.68 | 2025 | Mounjaro, Zepbound |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cordis US Corp. | $30.92 | 2025 | Mynxgrip |
| Bayer Healthcare Pharmaceuticals INC. | $28.98 | 2025 | |
| Esperion Therapeutics, INC. | $26.67 | 2025 | Nexletol |
| Alnylam Pharmaceuticals INC. | $22.46 | 2025 | Amvuttra |
| Edwards Lifesciences Corporation | $20.68 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.75 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $18.03 | 2025 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.